Nathan Sadeghi-Nejad

Nathan Sadeghi-Nejad has 15 years experience as a professional health-care investor, most recently as a sector head for Highside Capital. He has worked on the sell side (with independent research boutiques Sturza¿s Medical Research and Avalon Research) and the buyside (at Kilkenny Capital prior to Highside). Sadeghi-Nejad is a graduate of Columbia University and lives in New York. You can follow him on Twitter @natesadeghi.

Recent Articles By The Author

Celgene's Siren Song

Celgene's Siren Song

TheStreet Contributor Nate Sadeghi debates whether to buy Celgene ahead of a European decision on expanding use of its multiple myeloma drug Revlimid.

Outlooks for Pfizer, Arena and Onyx Following Busy May

Outlooks for Pfizer, Arena and Onyx Following Busy May

Healthcare investor Nate Sadeghi says Pfizer's arthritis drug and Arena's obesity drug will be approved, while confidence in Onyx's cancer drug has increased.

A Health Care Fortnight for the Record Books

A Health Care Fortnight for the Record Books

Health care investor Nate Sadeghi says Pfizer is holding back bad news on its Alzheimer's drug, tells Human Genome to sell to Glaxo and likes Vertex and Gilead Sciences.

Bristol-Myers Missing Hep C Data Raises Red Flags, May Boost Gilead, Idenix

Bristol-Myers Missing Hep C Data Raises Red Flags, May Boost Gilead, Idenix

A closer look at Bristol-Myers Squibb's hepatitis C drug BMS-094 raises troubling questions.

Grading Hep C Stocks Exiting EASL Confab

Grading Hep C Stocks Exiting EASL Confab

Healthcare investor Nathan Sadeghi-Nejad grades the hepatitis C drug stocks following the closely watched EASL conference.

Gilead, Bristol Hep C Drug Data Arrives at EASL

Gilead, Bristol Hep C Drug Data Arrives at EASL

The closely followed EASL meeting has begun with release of key hepatitis C drug data from Gilead and Bristol-Myers Squibb

Calling Shenanigans on Amylin Pharma

Calling Shenanigans on Amylin Pharma

Too many question, not enough answers regarding Bristol-Myers Squibb's supposed interest in buying Amylin.

Gilead And The Future of HIV Therapy

Gilead And The Future of HIV Therapy

Gilead's market dominance in HIV is not in peril but the company faces legitimate questions about its ability to innovate.

Regeneron, Amgen And The 'Hope Creation Cycle"

Regeneron, Amgen And The 'Hope Creation Cycle"

Cholesterol-lowering PCSK9 Inhibitors are real drugs but won't meet aggressive sales forecasts

On Nowruz, Reviewing Drug Stock Picks

On Nowruz, Reviewing Drug Stock Picks

TheStreet's biotech contributor Nathan Sadeghi-Nejad looks back at his hits and misses with Amylin, Elan, Gilead Sciences, Onyx and Verastem.